Passage Bio, Inc. Announces the Voluntary Transition of Jill Quigley as Chief Operating Officer
November 01, 2021 at 09:01 pm
Share
On November 1, 2021, Passage Bio, Inc. ("the Company") announced the voluntary transition of Jill Quigley, the Company's Chief Operating Officer, from the Company. Ms. Quigley is leaving the Company to pursue other
personal and professional interests, and her departure date will be December 31, 2021. Ms. Quigley's departure is not the result of any disagreements over the Company's business, operations, or strategic direction. Ms.
Quigley's responsibilities as Chief Operating Officer will be assumed by other members of the Company's executive team.
Passage Bio, Inc. is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Its clinical product candidate, PBFT02, seeks to elevate progranulin levels to restore lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus capsid to deliver a functional granulin gene, or GRN, encoding progranulin to the brain via intra cisterna magna administration. The lead indication for PBFT02 is frontotemporal dementia, or FTD, caused by progranulin deficiency, or FTD-GRN. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimerâs disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. It has one unnamed preclinical research program that explores multiple potential treatment targets for Huntington's disease.
PASSAGE BIO, INC. 
